Here is the latest news from our programme:
The KCE Trials Team |
Funding Opportunities
BeNeFIT-4 call : investigator-led call on comparative effectiveness studies, funding collaboration between the Netherlands and Belgium The 4th BeNeFIT-4 call for proposals on comparative effectiveness studies will open on October 28th 2024. The deadline for submissions is 14h on 28th January 2025. For full information, including inclusion and exclusion, as well as prioritisation criteria, please visit our website here. An online information session will be held on 5/11/2024.
|
Progress in funded studies
We are happy to announce the following important milestones have been reached in the trials below:
OPT-PEMBRO
| The contract has been recently signed for Belgian participation in the OPT-PEMBRO Sponsored by Unicancer (France). Belgian National Coordinator is Prof Francois Duhoux (Cliniques Universitaires St Luc) and the study will be performed in 10 sites in Belgium. |
Cerebral Palsy SDR vs ITB | The contract has been recently signed for the Cerebral Palsy SDR vs ITB BeNeFIT study. The CI is Prof Philippe De Vloo, Sponsor UZ Leuven. The study will be performed in 5 sites in Belgium and 2 in the Netherlands. |
HIT-HARD
| The HIT-HARD study compares a high dose short duration of antibiotics in critically ill patients versus a standard regimen. The Chief Investigator is Prof Jan De Waele , the sponsor is UZ Gent. The study will be performed in 7 sites in Belgium and 8 in the Netherlands.1282 patients will be included in both countries |
Direct TMS New study Contract signed | The contract has been signed for the DIRECT TMS study which aims at enhancing the treatment of major depressive disorder. This research will explore the combined effects of repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive Control Training (CCT). Funded under the BeNeFIT programme, the study will recrut in 4 sites in Belgium, coordinated by the team of Dr Chris Baeken (UZ Brussel). |
TELSTAR-2 New study Contract signed | The contract has been recently signed for the TELSTAR-2 BeNeFIT study. Evaluating treatment with anti-seizure medication in comatose cardiac arrest patients with status epilepticus on continuous electroencephalographic. In Belgium the National Coordinator is Prof. dr. Nicolas Gaspard and coordinating centre Hopital Universitaire de Bruxelles (HUB). Eight sites will recruit in Belgium. |
EPO-TRAUMA | In this international study, the effect of ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients will be studies compared to placebo. The coordinating investigator for Belgium is Prof Fabio Taccone, the coordinating centre is Hôpital Erasme (HUB). The study will run in 7 intensive care departments and will include 200 patients in Belgium (2500 internationally). |
SOPRANO | The SOPRANO trial compares two strategies to administer biological treatments to prevent postoperative endoscopic disease recurrence in Crohn's disease. The chief investigator is Prof. Dr. Ferrante from UZ Leuven. 352 participants will be included in this study across 24 sites. This study is also one of the first Belgian studies submitted through the CTIS, the new European platform for approval of clinical trials on drugs. |
ColbePCI | The COL BE PCI (COLchicine in BElgium in patients with coronary artery disease after Percutaneous Coronary Intervention) study (NCT06095765) has recruited 25% of planned participants. Congratulations to the CI Ian Buysschaert, the CO-Sponsors AZ Sint-Jan Brugge AV, and UZ Gent, the 18 sites and the entire team. |
HYFOIL | The HYFOIL RCT has reached an important milestone: 75% recruitment! This achievement brings us one step closer to understanding the impact of additional tubal flushing with oil-based contrast on fertility. Congratulations to Diane De Neubourg's team (UZA) and the 14 teams in the participating hospitals for this achievement ! |
TreatPaCS | 50% of the sample size has been achieved in the TreatPaCS study evaluating treatment options (Mini-KIDS, social cognitive behaviour treatment and the Lidcombe Program) for preschool age children who stutter. Congratulations to Chief Investigator Sabine Van Eerdenbrugh (TMMA) and co-chief investigators Veerle Waelkens (Artevelde) and Anne-Lise Leclercq (ULiège) and the 30 Speech Language Therapists in Belgium who participate in this study. |
The KCE Trials complete portfolio comprises 60 studies. more info>>
Impact
The latest scientific publications including results are presented below, and links to all publications can be found on the last tab of our dynamic dashboards.
More than 30 000 participants have been recruited so far in KCE funded trials!
Check our dynamic dashboard for real-time recruitment data for all KCE Trials funded studies
